Tags

42 pages

Research OS

Good Companies and Cheap Stocks Are Different Lists: Anatomy of Fourteen Korean Valuations

A Map of Biotech Investing: Where You Earn Only If the Drug Works, and Where You Earn Whichever Drug Works

Anatomy of the Rebound: Foreign Buying Came in Two Bursts, and the Same Two Stocks Changed Hands

AI's Bottleneck Really Is HBM, Not the GPU: But Bottlenecks Invite Workarounds

The Second Week of August in Review: AI Capital Moves to Wall Street, and Good News Starts Lasting Two Days

A Rebound Won't Come From a Single Trigger: A Verdict Calendar From Late August to Year-End

What Hyperscaler Earnings Proved, and What They Didn't: Three Explanations for the Memory Sell-Off

Memory No Longer Needs Prices to Rise Further: Anatomy of the August 3 Plunge and the Contract Price Deceleration

July Earnings Season Wrap: AI Demand Was Confirmed, and Memory Pricing Became an Industry-Wide Cost

Rebound or Terminal? Eight Doubts, Seven Discriminators, and a 48-Hour Verdict